Form 4: Hims & Hers Health CEO Andrew Dudum Executes Stock Options and Sells Shares
SEC Form 4 Filing
Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on April 28 and 29, 2025, according to a Form 4 filing with the SEC.
Summary
- Andrew Dudum, CEO of Hims & Hers Health, Inc., executed stock options to acquire Class A Common Stock at a price of $2.43 per share on April 28 and 29, 2025.
- He then sold these shares on the same days at weighted average prices of $30.186 and $36.3862, respectively.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024.
- Following these transactions, Dudum directly owns 92,103 shares of Class A Common Stock.
- He also indirectly owns significant amounts of Class A Common Stock through various trusts.
- After the transactions, Dudum directly owns 1,081,399 stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transactions were pre-planned and executed under a Rule 10b5-1 trading plan. The CEO selling shares could be perceived negatively, but the pre-planned nature mitigates this concern.
Positives
- The transactions were pre-planned under a Rule 10b5-1 trading plan, suggesting they were not based on insider information.
Negatives
- The CEO selling shares, even under a pre-arranged plan, could be perceived negatively by some investors.
Risks
- Further stock sales by the CEO could put downward pressure on the stock price.
Industry Context
Insider transactions are common and closely watched in the healthcare technology sector, as they can provide insights into management's confidence in the company's future prospects.
Comparison to Industry Standards
- Comparing Dudum's transactions to other CEOs in similar telehealth companies like Teladoc or Amwell would provide context on whether these sales are typical or unusual.
- Reviewing the frequency and size of insider sales at these comparable companies can help determine if this activity is aligned with industry norms.
Stakeholder Impact
- Shareholders may react to the CEO's stock sales, potentially impacting the stock price.
- Employees may be concerned about the CEO's confidence in the company, although the pre-planned nature of the sales should alleviate some concerns.
Key Dates
| Date | Description |
|---|---|
| March 13, 2020 | Beginning of monthly vesting for stock options received in exchange for Hims, Inc. options. |
| July 2, 2015 | Date of Andrew Dudum 2015 Trust. |
| August 10, 2021 | Date of Dudum Family Heritage Trust UAD. |
| November 1, 2021 | Date of AD 2021 GRAT and AD 2021 GRAT 2. |
| September 7, 2022 | Date of AD 2022 GRAT 2. |
| November 28, 2022 | Date of AD 2022 GRAT 3. |
| September 5, 2023 | Date of AD 2023 GRAT. |
| August 28, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| April 28, 2025 | Date of stock option exercise and sale of Class A Common Stock. |
| April 29, 2025 | Date of stock option exercise and sale of Class A Common Stock. |
| June 16, 2030 | Expiration date of stock options. |
Keywords
Hims & Hers Health, Andrew Dudum, stock options, Class A Common Stock, SEC Form 4, Rule 10b5-1, insider trading, stock sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.